NLN

Across TCGA pan-cancer cohorts, NLN mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NLN data layer compared with 30 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NLN mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NLN expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where NLN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.416	0.896	<.001	40	view →
HNSC	DFS	Median	All	0.698	1.000	.020	10	view →
CCRCC	DFS	Tertile	II,III,IV	0.242	0.972	.020	8	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	7	view →
GBM	OS	Median	All	0.278	0.451	.030	6	view →
LSCC	DFS	Median	II,III,IV	0.817	0.569	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NLN–PDAC (DFS)

Open the PDAC breakdown →